pd 153035 has been researched along with zd 6474 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A | 1 |
| Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A; Ravez, S; Six, P | 1 |
| Antonelli, A; Botta, L; Coviello, V; Da Settimo, F; Fallahi, P; Ferrari, SM; Hsing-Pang, H; Ke, YY; La Motta, C; La Pietra, V; Marinelli, L; Moriconi, A; Novellino, E; Quattrini, L; Sartini, S | 1 |
| Das, D; Hong, J | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
1 review(s) available for pd 153035 and zd 6474
| Article | Year |
|---|---|
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
4 other study(ies) available for pd 153035 and zd 6474
| Article | Year |
|---|---|
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Models, Molecular; Quinazolines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Structure-Activity Relationship; Thyroid Gland; Thyroid Neoplasms | 2018 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |